Intravenous Patient-Controlled Analgesia with Esketamine Improves Early Depressive Symptoms in Patients with Postherpetic Neuralgia: A Single-Center Retrospective Cohort Study

Abstract

Objective Patients with Postherpetic Neuralgia (PHN) often exhibit depressive-like symptoms, significantly impacting their quality of life. Esketamine, known for its analgesic properties, has also been recognized for its rapid antidepressant effects. However, its efficacy in the treatment of PHN requires further exploration. This study aims to evaluate the impact of intravenous patient-controlled analgesia with esketamine on depressive mood in PHN patients. Methods This retrospective study analyzed PHN patients hospitalized and treated at the affiliated hospital of Southwest Medical University from June 2021 to March 2023. Patients were divided into the esketamine group (E group) and the sufentanil group (S group) based on their treatment regimens. Primary outcomes included pain NRS, depression PHQ-9, and anxiety GAD-7 scores measured before treatment, and at 3 days, 7 days, 1 month, 2 months, and 3 months post-treatment. Results A total of 83 patients were included in the analysis. Before treatment, there were no statistically significant differences in pain NRS, depression PHQ-9, and anxiety GAD-7 scores between the two groups (P > 0.05). Compared to before treatment, significant reductions in pain NRS scores were observed at all post-treatment time points in both groups (P < 0.05), with no differences between groups (P > 0.05). The E group exhibited significantly lower depression PHQ-9 scores than the S group at 3 days and 7 days post-treatment (P < 0.05), but no significant differences were observed at 1 month, 2 months, and 3 months (P > 0.05). Anxiety GAD-7 scores were significantly lower in the E group compared to the S group at 3 days, 7 days, and 3 months post-treatment (P < 0.05), with no statistical differences at 1 month or 2 months post-treatment (P > 0.05). Conclusion Intravenous patient-controlled analgesia with esketamine not only alleviates pain in PHN patients but also improves early symptoms of anxiety and depression.